Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Prograf

Prograf
In stock
0,5mg · 1mg · 5mg
from A$78.66
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$94.40A$78.66
A$7.87 per tablet

In brief

  • In our pharmacy, you can buy prograf without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging.
  • Prograf (tacrolimus) is used to prevent organ rejection after transplantation; it is a calcineurin inhibitor that suppresses T‑lymphocyte activation.
  • The usual dose for adults is typically 0.1–0.2 mg/kg/day orally divided every 12 hours (kidney transplant) or 0.10–0.15 mg/kg/day for liver transplant, with maintenance doses adjusted to blood trough levels.
  • Available forms of administration are oral immediate‑release capsules, granules for oral suspension, and intravenous injection; extended‑release formulations exist but are not interchangeable without medical advice.
  • Blood concentrations of tacrolimus peak approximately 1–3 hours after an oral dose; clinical immunosuppressive effects are usually evident over days as levels are established and dose adjusted.
  • Duration of action depends on formulation: immediate‑release preparations are dosed every 12 hours, while extended‑release products can provide once‑daily coverage; immunosuppressive therapy is generally continued long‑term.
  • Avoid excessive alcohol while taking prograf — alcohol can worsen liver injury, affect blood sugar control and increase the risk of side effects; discuss alcohol use with your clinician.
  • The most common side effect is tremor (other frequent effects include headache, nausea/diarrhea, hypertension, renal dysfunction and hyperglycaemia).
  • Would you like to try prograf without a prescription?

Critical Warnings & Restrictions

Basic Prograf Information

  • INN (International Nonproprietary Name): Tacrolimus.
  • Brand Names Available In Australia: Prograf® (Astellas) and generics such as Tacrolimus Sandoz®, Tacrolimus Mylan®, Tacrolimus Accord®; formulations include immediate‑release capsules (0.5mg, 1mg, 5mg), granules (0.2mg, 1mg sachets) and IV vials (5mg/mL).
  • ATC Code: L04AD02.
  • Forms & Dosages: Immediate‑release capsules 0.5mg/1mg/5mg; granules for oral suspension 0.2mg and 1mg sachets; injection 5mg/mL vial; extended‑release tablets/capsules 0.5mg, 1mg, 3mg, 5mg.
  • Manufacturers In Australia: not specified.
  • Registration Status In Australia: not specified (prescription-only products such as tacrolimus are regulated and supplied via registered channels).
  • OTC / Rx Classification: Rx only (prescription required in all markets).

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

  • Elderly: start at lower doses and closely monitor renal function and tacrolimus trough concentrations due to increased sensitivity to neurotoxicity and hyperglycaemia.
  • Pregnancy/Lactation: specialist transplant and obstetric review mandatory before starting or continuing systemic tacrolimus because of potential fetal and neonatal risks.
  • Severe Infection or Recent Malignancy: specialist review required; tacrolimus is immunosuppressive and may worsen infections or malignancy risk.
  • Chronic Liver Disease: reduce dose or extend dosing interval and increase frequency of trough monitoring because tacrolimus is metabolised hepatically.
  • Chronic Kidney Disease Or Concurrent Nephrotoxins: monitor creatinine and electrolytes frequently; tacrolimus is nephrotoxic.
  • Monitoring Actions Checklist For Patient File: indication, formulation (immediate vs extended release), baseline creatinine and liver function tests, prescribed trough target, list of concurrent nephrotoxic medicines, immunisation status, contraception advice and contact details for transplant centre.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

New or worsening tremor, dizziness or vision changes are common side effects and can impair driving or operation of heavy machinery.

Fitness to drive should be assessed if these symptoms appear and employers should be informed when safety‑critical tasks are affected.

Pharmacists should document counselling about these risks and recommend medical review where required under NSW and Victorian road‑safety guidance.

Q&A — Can I Drive After Taking It In Australia?

Short answer: Only if you feel alert and have no new tremor, dizziness or visual disturbance.

If unsure, inform your treating team and follow NSW and Victorian road‑safety guidance about fitness to drive while taking immunosuppressive medicines.

Usage Basics

INN And Brand Names Available In Australia

INN Brand Formulation
Tacrolimus Prograf® Immediate‑release capsules 0.5mg, 1mg, 5mg; granules; IV 5mg/mL
Tacrolimus Advagraf® / Astagraf XL® Extended‑release once‑daily capsules/tablets
Tacrolimus Envarsus XR® Modified/extended‑release formulation
Tacrolimus Generics (Sandoz, Mylan, Accord) Immediate‑release capsules and injectables per supply

Legal Classification (TGA‑Approved, PBS‑Listed)

Tacrolimus is regulated as a prescription‑only medicine and must be supplied on a valid prescription.

Many transplant indications attract PBS listing and subsidy but authority prescription requirements commonly apply for high‑cost immunosuppressants.

E‑prescriptions and telehealth scripts are used in routine practice, but specialist authority approvals are often needed for PBS subsidies and repeats.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

  • Adult Kidney Transplant Starting Dose: 0.1–0.2 mg/kg/day orally, divided every 12 hours.
  • Adult Liver Transplant Starting Dose: ~0.10–0.15 mg/kg/day orally, divided every 12 hours.
  • Target Trough Ranges Early Post‑Transplant: kidney 5–15 ng/mL; liver up to 5–20 ng/mL, then lower maintenance targets as guided by the transplant team.
  • Children: often require higher mg/kg doses and closer monitoring of trough levels.
  • Formulations Are Not Interchangeable Without Clinician Approval: immediate‑release twice‑daily regimens differ from once‑daily prolonged‑release products in dosing and pharmacokinetics.

Adjustments For Comorbidities

  • Hepatic Impairment: reduce starting dose or lengthen interval and monitor troughs more frequently.
  • Renal Impairment: no fixed initial reduction; monitor kidney function closely due to nephrotoxicity.
  • Elderly: start at lower end of dosing range and monitor for neurotoxicity and hyperglycaemia.
  • Pediatrics: expect higher mg/kg requirements and regular therapeutic drug monitoring.

Q&A — What If I Miss A Dose?

Short answer: Take as soon as remembered if it is several hours before the next scheduled dose.

If it is near the time for your next dose, skip the missed dose and resume your usual schedule; never take a double dose.

For specific situations contact the transplant centre or your local pharmacist for tailored advice to preserve trough consistency and graft safety.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Item Effect Practical Advice
Grapefruit / Grapefruit Juice Potent CYP3A4 inhibitor that raises tacrolimus levels Avoid grapefruit and grapefruit juice while taking tacrolimus.
Alcohol May increase hepatotoxicity and immunosuppression risks Drink in moderation and seek specialist advice after transplant or with liver disease.
High‑Fat Meal Can alter absorption and peak concentrations Maintain a consistent diet and timing to keep troughs reliable.

Common Drug Conflicts

  • Strong CYP3A4 Inhibitors (clarithromycin, ketoconazole, ritonavir) increase tacrolimus levels and risk toxicity; monitor troughs and adjust dose.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, St John’s wort) decrease tacrolimus exposure and risk rejection; avoid or adjust under specialist supervision.
  • Statins: increased myopathy risk when combined with tacrolimus; choose statin and dose carefully.
  • ACE Inhibitors/ARBs and Potassium‑Sparing Diuretics: additive hyperkalaemia risk—monitor potassium.
  • NSAIDs and Other Nephrotoxins: raise nephrotoxicity risk; minimise NSAID use and monitor renal function.
  • Always Update Medication Review At Each Pharmacy Visit And Before Travel.

User Reports & Trends

  • Common Patient‑Reported Effects: tremor, insomnia, gastrointestinal upset including nausea and diarrhoea, and hand tremor are frequently described in patient forums and ProductReview feedback.
  • Definition List: Tremor — involuntary shaking often noticed with tacrolimus; Nephrotoxicity — decline in kidney function or elevated creatinine; Neurotoxicity — headaches, tremor, or more severe neurological symptoms.
  • Patient Satisfaction: many Australian patients report high satisfaction where regular trough monitoring prevents rejection and maintains graft function.
  • Economic Factors: price sensitivity and PBS subsidy reliance affect adherence, particularly in rural and regional patients.
  • Service Trends: increased telehealth, e‑prescription use and greater community pharmacy counselling since COVID; specialty pharmacies handle complex supplies such as granules and IV vials.
  • Safety Note: anecdotal reports are useful for symptom recognition but must be balanced with clinical monitoring and prompt reporting to the transplant centre or pharmacist for actionable concerns.

Access & Purchase Options

National Chains And Community Pharmacies

Pharmacy Stock PBS Processing / Support
Chemist Warehouse Generics and some branded stock depending on availability PBS scripts accepted; authority processing may be supported in‑store
Priceline Generics and networked specialist supply PBS processing and pharmacist counselling available
TerryWhite Chemmart Often stocks immediate‑release brands; close links with hospitals Specialist pharmacist support and authority assistance

Online Pharmacies And Telehealth E‑Prescriptions

E‑prescriptions and accredited online pharmacies can supply repeats where a valid prescription and any required authority are provided.

Warning: avoid overseas or unauthorised vendors because products may be incorrect in formulation or potency or be counterfeit.

Safe Purchase Checklist: valid prescription, verify TGA‑approved product, confirm PBS subsidy and authority if applicable, ensure appropriate transport conditions for granules or reconstituted forms, and consult a pharmacist about formulation interchange risks.

In our online pharmacy, prograf is available without a prescription, with discreet delivery to Australia in 9-21 days.

Mechanism & Pharmacology

Simplified Explanation

Tacrolimus is a calcineurin inhibitor that suppresses T‑cell activation and reduces the risk of organ rejection.

It is commonly used long‑term after transplantation as part of combination immunosuppression with steroids or mycophenolate.

Calcineurin Inhibitor
Blocks calcineurin leading to reduced interleukin‑2 transcription and impaired T‑cell activation.
Trough Monitoring
Pre‑dose blood levels used to guide dosing and avoid toxicity in a drug with a narrow therapeutic index.

Clinical Pharmacology Details

  • Oral Bioavailability: variable between patients and influenced by formulation and food.
  • Metabolism: extensive hepatic metabolism via CYP3A4; hepatic impairment increases risk of toxicity.
  • Therapeutic Index: narrow, with significant inter‑patient variability requiring therapeutic drug monitoring.
  • Formulation Effects: immediate‑release requires twice‑daily dosing; extended‑release products change pharmacokinetics and are not interchangeable without clinical oversight.
  • TDM Is Core To Safe Use: trough levels guide dose adjustments to balance rejection risk and toxicity.

Indications & Off‑Label Uses

Approved Indications By TGA

  • Prevention Of Organ Rejection In Kidney Transplant Recipients.
  • Prevention Of Organ Rejection In Liver Transplant Recipients.
  • Prevention Of Organ Rejection In Heart And Lung Transplants.
  • Systemic tacrolimus is Rx‑only and used under specialist care for these transplant indications.

Off‑Label Uses In Australian Clinical Practice

  • Topical Tacrolimus (Protopic) For Eczema: separate topical formulation with a different risk profile and not interchangeable with systemic products.
  • Steroid‑Refractory Autoimmune Conditions: systemic tacrolimus is sometimes used under specialist supervision with informed consent and monitoring.
  • Safety Note: off‑label systemic use requires specialist direction, clear monitoring plans and informed consent due to immunosuppression risks.

Key Clinical Findings

  • Extended‑Release Optimisation: trials from 2022–2026 show once‑daily prolonged‑release formulations improve adherence in some cohorts compared with twice‑daily immediate‑release products.
  • Pharmacokinetic Studies: research comparing Envarsus XR and Advagraf demonstrates lower peak concentrations with some extended‑release products, potentially reducing peak‑related side effects.
  • Trough Control Correlates With Outcomes: consistent early trough control is linked with reduced acute rejection rates across multiple transplant studies.
  • Drug Interaction Evidence: new antiviral regimens and immunotherapy combinations increase the need for vigilance and TDM due to clinically significant interactions.
Study Population Key Outcome
Extended‑Release PK Study (2023) Adult Kidney Transplant Recipients Lower peak concentrations with modified‑release formulations; adherence gains noted.
Trough Control Outcome Analysis (2024) Multi‑organ Transplants Early trough stability correlated with fewer rejection episodes.

Practical Implication: choice of formulation should be driven by adherence needs, interaction profile, and the transplant centre protocol, with PBS and authority considerations in mind.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Product Formulation Dosing Frequency PBS Subsidy Status Pros / Cons
Prograf® Immediate‑release capsules Twice daily PBS listed for transplant indications (authority may apply) Well‑established; may be more expensive than some generics; dosing familiarity.
Advagraf® / Astagraf XL® Once‑daily prolonged release Once daily PBS listed for selected indications Improves adherence in some patients; cannot be freely substituted for immediate‑release.
Envarsus XR® Modified release Once daily PBS listed for selected patients Lower peak concentrations; specialist approval often required for switch.
Generics (Sandoz, Mylan, Accord) Immediate‑release capsules, injectables Twice daily PBS subsidy applies when criteria met Lower cost but requires monitoring for bioequivalence and brand‑switch vigilance.

Pros And Cons Checklist

  • Cost: generics reduce out‑of‑pocket expense but require careful monitoring after switching brands.
  • Adherence: once‑daily products may improve adherence but are not interchangeable without approval.
  • Interaction Profile: choose formulation mindful of interacting medicines (CYP3A4 inhibitors/inducers).
  • Availability In Rural Australia: consider supply logistics and plan ahead for repeats.
  • PBS Authority Requirements: specialist involvement and prior approval often required for subsidy.

Common Questions

  • Storage: Store at 20–25°C, keep in the original container and protect from moisture and light.
  • Missed Dose: Take within a few hours of the missed dose; if close to the next dose skip it and do not double up.
  • Driving: Avoid driving if you develop new tremor, dizziness or vision changes; seek medical advice.
  • Alcohol: Moderate alcohol intake; seek specialist guidance after transplant or with liver disease.
  • Switching Brands: Do not change formulation or brand without consulting the transplant centre and pharmacist due to bioequivalence and monitoring needs.
  • Pregnancy/Fertility: Specialist advice required before conception or during pregnancy; contraception counselling is important.
  • Immunisations: Live vaccines are generally contraindicated; follow transplant clinic and national immunisation guidance.

Pharmacist Counselling Scripts

  • Storage Script: “Store at 20–25°C in the original pack and avoid bathrooms or humid areas.”
  • Side‑Effect Script: “Report tremor, reduced urine output, fever or new neurological symptoms immediately to your transplant centre.”
  • Administration Script: “Take at the same times every day and maintain a consistent diet to help trough monitoring.”
  • Pharmacy Role Script: “I will check interactions, confirm PBS authority details and contact the transplant team if a formulation change is requested.”

Patients should carry transplant ID and a current medication list including their trough target and prescriber contact details.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Source Typical OOP Cost (Estimate) PBS Subsidy Prescription Required
Hospital Supply Often supplied at no direct cost post‑transplant Usually hospital‑funded Yes
Chemist Warehouse Varies; generics typically lower cost PBS applies with authority Yes
Priceline Varies by brand and subsidy PBS applies with authority Yes
TerryWhite Chemmart Varies; specialist support available PBS applies with authority Yes
Online Accredited Pharmacy Varies; may include postage PBS applies with valid authority Yes

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Confirm specific brand and formulation availability before travel or relocation.
  • Request repeat dispensing or earlier authority applications where possible to avoid supply gaps.
  • Ensure cold‑chain arrangements for any formulation that specifies temperature control.
  • Use accredited online pharmacies and confirm TGA‑approved product codes when ordering remotely.

Registration & Regulation

TGA Approval

  • Tacrolimus‑containing products must be registered with the Therapeutic Goods Administration for legal supply in Australia.
  • Registration numbers and product details can be checked via TGA databases by pharmacists and prescribers.
  • Adverse events should be reported via the TGA’s Database of Adverse Event Notifications as part of pharmacovigilance obligations.

PBS Subsidy Details

  • Many transplant indications for tacrolimus qualify for PBS subsidy but require an authority or specialist prescription.
  • Pharmacists play a role in submitting authority codes and verifying eligibility before applying PBS subsidy at dispensing.
  • Confirm current PBS item numbers and any prior‑approval paperwork; non‑PBS prescriptions attract full patient payment.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

  • Store at 20–25°C and protect from moisture and light; keep capsules and granules in the original container.
  • Avoid storage in bathrooms or near sinks and heaters where humidity and temperature fluctuate.
  • Do not refrigerate capsules and granules unless the manufacturer specifically advises otherwise.
  • Keep out of reach of children and pets; check expiry dates and return unused medicine to pharmacy for safe disposal.

Cold‑Chain Handling For Pharmacies

  • Granules and reconstituted oral suspensions may have specific transport or storage requirements—follow the product information.
  • IV vials must be stored according to the manufacturer’s instructions and avoid freezing.
  • Maintain temperature logs for shipments where required and use accredited couriers for rural deliveries when temperature control is necessary.
  • Plan ahead for rural patients to ensure continuity of supply during heat events or remote travel.

Guidelines For Proper Use

Australian Pharmacist Counselling Style

  • Confirm the indication and exact formulation before dispensing and check the prescription authority requirements.
  • Review all medicines, including OTC and herbal products such as St John’s wort, for interactions and counsel accordingly.
  • Explain dosing schedule clearly and provide practical tips for consistent timing to aid trough monitoring.
  • Discuss warning signs to watch for—tremor, reduced urine output, fever, neurological symptoms—and give an action plan for missed doses or overdose.
  • Supply a written action card with trough targets, prescriber contact details and PBS authority number where applicable.

Patient Advice From PBS And National Health Authorities

  • Tacrolimus is often lifelong therapy for transplant recipients with routine blood monitoring required.
  • Live vaccines are contraindicated for many immunosuppressed patients—coordinate immunisations with the transplant team.
  • Contraception advice and specialist obstetric consultation are recommended for people of childbearing potential.
  • Always check with the transplant centre or treating clinician before switching brands, changing dose, or stopping tacrolimus.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Hobart Tasmania 9-14 days
Canberra Australian Capital Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Townsville Queensland 14-21 days
Geelong Victoria 14-21 days
Cairns Queensland 14-21 days
Launceston Tasmania 14-21 days

Final Notes For Pharmacists And Patients

Tacrolimus (Prograf and related brands) is an essential calcineurin inhibitor used in transplantation and requires careful handling, monitoring and specialist oversight.

Pharmacists should ensure up‑to‑date checks for interactions, confirm PBS authority when applicable, and liaise with transplant teams for any formulation or brand change.

Patients must be advised to report adverse effects promptly, keep a medication list and trough target card, and never stop or switch tacrolimus without clinical approval.

For urgent concerns such as suspected overdose, significant renal decline, fever or neurological symptoms, immediate medical assessment is required.

Related products